WallStreetZenWallStreetZen

NASDAQ: ACXP
Acurx Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for ACXP

Based on 3 analysts offering 12 month price targets for Acurx Pharmaceuticals Inc

Min Forecast
$31.00+507.84%
Avg Forecast
$143.67+2,717%
Max Forecast
$240.00+4,605.88%

Should I buy or sell ACXP stock?

Based on 3 analysts offering ratings for Acurx Pharmaceuticals Inc.

Buy
Strong Buy
0 analysts 0%
Buy
3 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although ACXP's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates ACXP as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their ACXP stock forecasts and price targets.

ACXP stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-08-12
lockedlocked$00.00+00.00%2025-05-15
lockedlocked$00.00+00.00%2025-03-19

1 of 1

Forecast return on equity

Is ACXP forecast to generate an efficient return?

Company
-1,395.33%
Industry
122.74%
Market
-47.8%
ACXP's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ACXP forecast to generate an efficient return on assets?

Company
-808.1%
Industry
46.26%
ACXP is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ACXP earnings per share forecast

What is ACXP's earnings per share in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$7.14
Avg 2 year Forecast
-$6.03
Avg 3 year Forecast
-$4.83

ACXP revenue forecast

What is ACXP's revenue in the next 1 years based on estimates from 1 analyst?

Avg 1 year Forecast
$3.4M

ACXP vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ACXP$5.10$143.67+2,717.00%Buy
VYNE$0.32$4.50+1,315.09%Buy
CELZ$3.16N/AN/A
CAPS$1.42N/AN/A
ADIL$0.38N/AN/A
View Top Biotech Stocks

Acurx Pharmaceuticals Stock Forecast FAQ

Is Acurx Pharmaceuticals Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: ACXP) stock is to Buy ACXP stock.

Out of 3 analysts, 0 (0%) are recommending ACXP as a Strong Buy, 3 (100%) are recommending ACXP as a Buy, 0 (0%) are recommending ACXP as a Hold, 0 (0%) are recommending ACXP as a Sell, and 0 (0%) are recommending ACXP as a Strong Sell.

If you're new to stock investing, here's how to buy Acurx Pharmaceuticals stock.

What is ACXP's earnings growth forecast for 2025-2027?

(NASDAQ: ACXP) Acurx Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.32%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.39%.

Acurx Pharmaceuticals's earnings in 2025 is -$9,998,860.On average, 1 Wall Street analyst forecast ACXP's earnings for 2025 to be -$11,315,294, with the lowest ACXP earnings forecast at -$11,315,294, and the highest ACXP earnings forecast at -$11,315,294. On average, 1 Wall Street analyst forecast ACXP's earnings for 2026 to be -$9,556,193, with the lowest ACXP earnings forecast at -$9,556,193, and the highest ACXP earnings forecast at -$9,556,193.

In 2027, ACXP is forecast to generate -$7,654,463 in earnings, with the lowest earnings forecast at -$7,654,463 and the highest earnings forecast at -$7,654,463.

What is ACXP's revenue growth forecast for 2029-2029?

(NASDAQ: ACXP) Acurx Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 82.98%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.98%.

Acurx Pharmaceuticals's revenue in 2025 is $0.

In 2029, ACXP is forecast to generate $5,324,844 in revenue, with the lowest revenue forecast at $5,324,844 and the highest revenue forecast at $5,324,844.

What is ACXP's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: ACXP) forecast ROA is -808.1%, which is lower than the forecast US Biotechnology industry average of 46.26%.

What is ACXP's Price Target?

According to 3 Wall Street analysts that have issued a 1 year ACXP price target, the average ACXP price target is $143.67, with the highest ACXP stock price forecast at $240.00 and the lowest ACXP stock price forecast at $31.00.

On average, Wall Street analysts predict that Acurx Pharmaceuticals's share price could reach $143.67 by Aug 12, 2026. The average Acurx Pharmaceuticals stock price prediction forecasts a potential upside of 2,717% from the current ACXP share price of $5.10.

What is ACXP's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: ACXP) Acurx Pharmaceuticals's current Earnings Per Share (EPS) is -$10.69. On average, analysts forecast that ACXP's EPS will be -$7.14 for 2025, with the lowest EPS forecast at -$7.14, and the highest EPS forecast at -$7.14. On average, analysts forecast that ACXP's EPS will be -$6.03 for 2026, with the lowest EPS forecast at -$6.03, and the highest EPS forecast at -$6.03. In 2027, ACXP's EPS is forecast to hit -$4.83 (min: -$4.83, max: -$4.83).

What is ACXP's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: ACXP) forecast ROE is -1,395.33%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.